(Q37836931)

24 August 2017

1 reference

title

Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. (English)

1 reference

24 August 2017

1 reference

Amanda J Redig

1

1 reference

24 August 2017

Eliza Vakana

series ordinal

2

1 reference

24 August 2017

Leonidas C Platanias

series ordinal

3

1 reference

24 August 2017

language of work or name

1 reference

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

52 Suppl 1

1 reference

24 August 2017

45-53

1 reference

Translation of the Philadelphia chromosome into therapy for CML.

24 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Applying the discovery of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Map kinase signaling pathways and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Regulation of MAP Kinase Signaling Modules by Scaffold Proteins in Mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Signal transduction by MAP kinases in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

MAP kinases in the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Regulation of the immune response by stress-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Calcium-stimulated mitogen-activated protein kinase activation elicits Bcl-xL downregulation and Bak upregulation in notexin-treated human neuroblastoma SK-N-SH cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

CCN3: a key growth regulator in Chronic Myeloid Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Characterization of cancer stem cells in chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Targeting of gene expression by siRNA in CML primary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Exploiting the mammalian target of rapamycin pathway in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Growth suppressive cytokines and the AKT/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

21 January 2018

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

mTOR signaling: at the crossroads of plasticity, memory and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

Resistance to imatinib mesylate in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546919

10.3109/10428194.2010.546919

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference